Search Results
Your search for ,wAS matches 27442 pages
Showing 13151 - 13200Addition of Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC
New research published by Bagley et al in JNCCN—Journal of the National Comprehensive Cancer Network used a large real-world data set to demonstrate a modest but consistent survival benefit associated with adding bevacizumab to carboplatin/pemetrexed in advanced nonsquamous non–small...
Median Lag Time for First-in-Human to First-in-Child Oncology Trials
Cancer drugs approved by the U.S. Food and Drug Administration (FDA) took a median of 6.5 years to advance from the first clinical trial in adults to the first trial in children, according to a study published by Neel et al in the European Journal of Cancer. “Despite knowing that these...
Polatuzumab Vedotin and Immunochemotherapy in Previously Untreated Diffuse Large B-Cell Lymphoma
As reported in The Lancet Oncology, Tilly et al found that the combination of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, with immunochemotherapy showed high response rates in the phase II portion of a phase I/II study in previously...
CheckMate 032: Extended Follow-up of Nivolumab and Nivolumab/Ipilimumab Cohorts in Previously Treated Metastatic Urothelial Carcinoma
As reported in the Journal of Clinical Oncology by Sharma et al, follow-up of the cohort receiving nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg the phase I/II CheckMate 032 trial showed the regimen produced high levels of activity in platinum-treated, unresectable, locally advanced or metastatic ...
GeparSepto: Long-Term Clinical Outcomes With Neoadjuvant Nab-paclitaxel vs Solvent-Based Paclitaxel in Early Breast Cancer
As reported in the Journal of Clinical Oncology by Untch et al, long-term follow-up in the GeparSepto trial showed that patients with early breast cancer receiving neoadjuvant nab-paclitaxel vs solvent-based paclitaxel followed by epirubicin/cyclophosphamide had better invasive disease–free...
Stand Up To Cancer Names Grant Recipients of ‘Innovation in Collaboration’
The Phillip A. Sharp Awards for Innovation in Collaboration, are named for Phillip A. Sharp, PhD, Nobel Laureate, and molecular biologist at Massachusetts Institute of Technology, in recognition of his emphasis on collaboration across research institutions and different teams. Stand Up To Cancer...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Breast Cancer Specialist Focuses on Educational Side of Oncology, Connecting Patients With Cancer Around the World
Internationally renowned breast cancer specialist Daniel A. Vorobiof, MD, was born in Santa Fe, Argentina, a province in the northeastern region of the country that is prone to catastrophic flooding. Asked about any early influences in his desire to pursue a career in medicine, Dr. Vorobiof...
AACR Inaugurated New Leadership at 2019 Annual Meeting
The American Association for Cancer Research (AACR) inaugurated Elaine R. Mardis, PhD, as President for 2019–2020 during the 2019 AACR Annual Meeting. Dr. Mardis holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is Co–Executive Director of the Institute for Genomic Medicine at...
James P. Allison, PhD
James P. Allison, PhD, is Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center in Houston. In 2018, Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine, with Tasuku Honjo, MD, PhD, for launching an effective...
Cancer Researcher Continues to Push the Envelope in Immunotherapy to Help Patients Live Longer
Nationally regarded cancer immunologist Padmanee Sharma, MD, PhD, was born and reared in Georgetown, Guyana, on South America’s North Atlantic coast, noted for being the only South American country in which English is the official language. Her parents were descendants of indentured immigrants...
A Career Path Balancing Research, Patient Care, and Everyday Life
In elementary school, Laurie H. Sehn, MD, MPH, dreamed of becoming a teacher. However, as she moved through high school, her passion for science blossomed, as did her desire to have an impact on people’s lives. “I began to seriously consider medicine because it provided the dual opportunity to...
FDA Oncology Drug Approvals Granted Between May 21, 2018 and May 14, 2019
Over the past year (May 2018–May 2019), the U.S. Food and Drug Administration (FDA) granted approval and accelerated approval to a number of new oncology drugs and biosimilars. Here we list the new FDA-approved labels and indications. AVELUMAB (BAVENCIO) and AXITINIB (INLYTA) has been approved as a ...
FDA Approves Lenalidomide in Combination for Previously Treated Follicular and Marginal Zone Lymphomas
Today, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) in combination with a rituximab product for previously treated follicular and marginal zone lymphoma. AUGMENT and MAGNIFY Trials Approval was based on two clinical trials: AUGMENT and MAGNIFY. In AUGMENT, 358...
FDA Approves Alpelisib in Combination With Fulvestrant for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
On May 24, the U.S. Food and Drug Administration (FDA) approved alpelisib (Piqray) tablets to be used in combination with the FDA-approved endocrine therapy fulvestrant to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...
Risk of Subsequent Breast Cancer in Female Childhood Cancer Survivors
As reported by Ehrhardt et al in the Journal of Clinical Oncology, high doses of anthracyclines were associated with increased breast cancer risk in female childhood cancer survivors in the St. Jude Lifetime Cohort Study, with the association being independent of mutations in cancer risk...
FDA Approves the NovoTTF-100L System in Combination With Chemotherapy for Malignant Pleural Mesothelioma
On May 23, the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma. NovoTTF-100L is a noninvasive,...
FDA Approves Ruxolitinib for Acute Graft-vs-Host Disease
On May 24, the U.S. Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) for steroid-refractory acute graft-vs-host disease (GVHD) in adult and pediatric patients 12 years and older. REACH1/Study INCB 18424-271 Approval was based on the REACH1 trial/Study INCB 18424-271, an...
Emily Whitehead, Early Recipient of CAR T-Cell Therapy for ALL, Celebrates 7 Years Cancer-Free
Among the success stories in the treatment of acute lymphoblastic leukemia (ALL) in children and young adults is the development of chimeric antigen receptor (CAR) T-cell therapy. The field of cellular immunotherapy was still in its infancy in 2012 when Emily Whitehead, then 7, became the first...
Triplet Chemotherapy in Unresectable Locally Advanced or Metastatic Biliary Tract Cancers
In a phase II trial reported in JAMA Oncology, Rachna T. Shroff, MD, and colleagues found that the addition of nab-paclitaxel to standard gemcitabine and cisplatin resulted in promising outcomes in patients with unresectable locally advanced or metastatic biliary tract cancers. The study included...
Fulvestrant/Anastrozole in Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Rita S. Mehta, MD, and colleagues, the final overall survival results of the phase III SWOG S0226 trial show that the addition of first-line fulvestrant to anastrozole was associated with improved overall survival in postmenopausal women with...
AYA Survivors Should Be Allowed to Participate in Adult Clinical Trials
When strangers ask me how many children I have, I’m not quite sure how to respond. Do I still have four children even though one has died? A year and a half after my son Brent’s death, at the age of 18, from complications of acute myeloid leukemia (AML), I’m still struggling with knowing the...
Unlocking the Secrets of the Immune System, Story by Story
The story of immunotherapy is one of the most interesting and provocative in medical history. William B. Coley, MD, first harnessed the immune system against cancer in the late 19th century by injecting mixtures of live and inactivated bacteria into patients’ tumors. For various reasons,...
An Insider’s Account of the Nobel Prize–Winning Race to Uncover the Secret of the Ribosome
Situated in the nucleus of the human cell is DNA, the secret of life discovered by the Nobel Prize laureates Drs. Watson and Crick. More recently, another scientist, Venki Ramakrishnan, PhD, won a Nobel Prize for his work in uncovering another secret within the human cell: the structure of the...
Lifestyle Modifications and Screening of Patients at High Risk Can Reduce Deaths From Pancreatic Cancer
After disclosing that he had been diagnosed with stage IV pancreatic cancer, Alex Trebek, longtime host of the popular television game show Jeopardy!, vowed that he would beat the disease despite the low associated survival rate. His statement has brought pancreatic cancer back into the public...
AACR Inaugurated New Leadership at 2019 Annual Meeting
The American Association for Cancer Research (AACR) inaugurated Elaine R. Mardis, PhD, as President for 2019–2020 during the 2019 AACR Annual Meeting. Dr. Mardis holds the Nationwide Foundation Endowed Chair in Genomic Medicine and is Co–Executive Director of the Institute for Genomic Medicine at...
Rookie
His steps generated a low rumble that propagated through the floor like a tsunami, flowed up through my desk, and ended as tiny waves visible through the clear plastic of my water bottle. His custom Lucchese ostrich boots made a distinctive clicking sound as they rhythmically struck the tile floor, ...
FDA Approves Ramucirumab for Hepatocellular Carcinoma
ON MAY 10, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza) as a single agent for hepatocellular carcinoma in patients who have an alpha fetoprotein (AFP) level ≥ 400 ng/mL and have been previously treated with sorafenib. REACH-2 Trial APPROVAL WAS based on the REACH-2...
NCCN Recognizes Five Individuals for Achievements in Cancer Care
THE NATIONAL Comprehensive Cancer Network® (NCCN®) has announced the recipients of a series of awards honoring individuals whose contributions have fueled progress in improving and facilitating quality, effective, efficient, and accessible cancer care over the past year. They are Timothy J....
Debating the Role of Opioids in the Management of Chronic Cancer Pain
Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving...
Andrew T. Chan, MD, MPH, Receives 2019 AACR–Waun Ki Hong Award
The American Association for Cancer Research (AACR) recently awarded Andrew T. Chan, MD, MPH, with the 2019 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research during the 2019 AACR Annual Meeting. Dr. Chan is recognized for his work on the molecular...
USC Norris Comprehensive Cancer Center Appoints Caryn Lerman, PhD, as Director
Caryn Lerman, PhD, has been appointed Director of the USC Norris Comprehensive Cancer Center, also serving as Professor of Psychiatry and the Behavioral Sciences. Prior to this appointment, Dr. Lerman was the John H. Glick Professor for Cancer Research and Vice Dean for Strategic Initiatives in...
Otis W. Brawley, MD, MACP, FASCO: Doctor, Policy Advocate, Writer, and Champion of the Underserved
In this installment of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with Otis W. Brawley, MD, MACP, FASCO, a global leader in cancer research and health disparities. Dr. Brawley, who served as Chief Medical and Scientific Officer for the American Cancer Society (ACS) and...
Barriers to Cervical Cancer Screening Among HIV-Infected Women in Tanzania
Population screening programs and the advent of human papillomavirus (HPV) vaccination have made cervical cancer largely a preventable disease. Despite these advances, cervical cancer remains a leading cause of cancer death for women in low- and middle-income countries. A recent study identified...
Capsaicin
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, explore the use of...
Francoise Mornex, MD, PhD, Named First Female Recipient of Heine H. Hansen Award
The European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) recently awarded the 2019 Heine H. Hansen Award to Francoise Mornex, MD, PhD. The award was presented at the 2019 European Lung Cancer Congress. Dr. Mornex is Professor of...
Ghanaian Oncologist Yehoda M. Martei, MD, Seeks Ways to Improve Outcomes in the Developing World
Breast cancer remains the most commonly diagnosed cancer among women globally. Due to a lack of early interventions, most women in low- and middle-income countries have advanced disease at the time of diagnosis, conferring a grim prognosis. Yehoda M. Martei, MD, of the Department of Medicine,...
Measuring the Burden of Global Cancer as a Tool for Policymakers
The Global Burden of Disease Study was initiated in 1990, commissioned by the World Bank. At that time, the study was conducted mainly by researchers at Harvard and the World Health Organization (WHO). Since then the study has gone through many iterations to its present structure, which is a...
Uniting the Global Cancer Community to Reduce Deaths From Noncommunicable Diseases
It has been well documented that noncommunicable diseases, including cancer, cardiovascular disease, and diabetes, now pose the greatest health threat to people living in low- and middle-income countries, surpassing infectious diseases like HIV/AIDS as the leading cause of death and disability.1...
Margo Shoup, MD, FACS, Appointed Network Chair of Nuvance Health Cancer Service Line
Margo Shoup, MD, FACS, has been appointed Network Chair of the Cancer Service Line for the new health system formed by Health Quest and Western Connecticut Health Network (WCHN), to be called Nuvance Health. Dr. Shoup will provide strategic and clinical leadership for all aspects of Nuvance...
AACR Honors Elaine Fuchs, PhD, With 2019 AACR G.H.A. Clowes Memorial Award
The American Association for Cancer Research (AACR) has awarded the 59th AACR G.H.A. Clowes Memorial Award to Elaine Fuchs, PhD. The award was presented during the AACR Annual Meeting 2019. Dr. Fuchs delivered her award lecture, “Stem Cells in Wound Repair, Inflammation, and Cancer,” at the Georgia ...
St. Jude Children’s Research Hospital and WHO Join Forces to Improve Childhood Cancer Survival Worldwide
A report by the International Agency for Research on Cancer (IARC) based on data from more than 100 cancer registries in 68 countries shows that from 2001 to 2010, the occurrence of childhood cancer worldwide was 13% more common than in the 1980s.1 In addition, the report’s findings showcase stark...
How Cancer Affects Adolescents and Young Adults
The statistics are alarming: according to the National Cancer Institute (NCI), about 70,000 adolescents and young adults (AYAs) are diagnosed with cancer each year1—a recent report by the University of California put that figure at 87,000.2 Although overall cancer survival rates continue to improve ...
New Radiation Options for Localized Prostate Cancer May Improve Patient Outcomes
External-beam radiation therapy (EBRT) is a standard treatment option for men with localized prostate cancer and confers long-term prostate cancer control outcomes equal to radical prostatectomy. Technologic advances in imaging and computing during the past 20 years have led to a number of...
Charles G. Mullighan, MBBS (Hons), MSc, MD, Named St. Jude Comprehensive Cancer Center Deputy Director
The St. Jude Children’s Research Hospital Comprehensive Cancer Center has appointed Charles G. Mullighan, MBBS (Hons), MSc, MD, as its new Deputy Director. In this new position, Dr. Mullighan will help guide precision medicine and preclinical strategic research initiatives for the Center, which is...
Anjali Mishra, PhD, and Nitin Chakravarti, PhD, Join Sidney Kimmel Cancer Center at Jefferson Health
The Sidney Kimmel Cancer Center–Jefferson Health (SKCC) recently welcomed Anjali Mishra, PhD, and Nitin Chakravarti, PhD, to its team of researchers focused on hematologic cancers. Both Drs. Mishra and Chakravarti are Assistant Professors in the Department of Medical Oncology. Dr. Mishra is a...
Erdafitinib for Metastatic Urothelial Carcinoma
On April 12, 2019, erdafitinib was granted accelerated approval for patients with locally advanced or metastatic urothelial carcinoma with susceptible fibroblast growth factor receptor 3 (FGFR3) or FGFR2 genetic alterations, when the disease has progressed during or following platinum-containing...
FDA Approves Chemotherapy-Free Regimen, Venetoclax Plus Obinutuzumab, as First-Line Treatment for CLL/SLL
On May 15, the U.S. Food and Drug Administration (FDA) approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approval was based on the CLL14...
FDA Expands Pembrolizumab Indication for NSCLC in First-Line Setting
On April 14, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with stage III non–small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or those with metastatic NSCLC....
Baylor Scott & White Health Names New Chief of Oncology, Ronan Kelly, MBBCh, MD, MBA
Baylor Scott & White Health, the largest not-for-profit health-care system in Texas, recently named Ronan Kelly, MBBCh, MD, MBA, Chief of Oncology for the organization’s North Texas medical centers. Dr. Kelly’s leadership will span Baylor University Medical Center—the System’s North Texas...
